Familial Hypercholesterolaemia for MRCP Part 1: High-Yield Lipid Disorders
- Crack Medicine
- 18 hours ago
- 5 min read
TL;DR
Familial hypercholesterolaemia (FH) is one of the most important inherited lipid disorders tested in MRCP Part 1. It is usually caused by mutations affecting LDL receptor function, leading to markedly elevated LDL cholesterol, tendon xanthomas and premature atherosclerotic cardiovascular disease. Candidates should focus on recognising the characteristic clinical features, understanding inheritance patterns and knowing the principles of diagnosis and management.
Why Familial Hypercholesterolaemia Matters for MRCP Part 1
Familial hypercholesterolaemia is a classic examination topic because it integrates genetics, metabolism and cardiovascular medicine. It is among the commonest inherited metabolic disorders and carries a substantial risk of premature coronary artery disease if left untreated.
For MRCP candidates, FH frequently appears in clinical vignettes involving:
Young patients with myocardial infarction
Family histories of premature cardiovascular disease
Tendon xanthomas
Isolated elevations in LDL cholesterol
Questions on lipid-lowering therapies
A strong understanding of FH also strengthens broader knowledge of dyslipidaemia and preventive cardiology.
For a complete overview of the examination curriculum, visit the MRCP Part 1 hub:
Understanding Familial Hypercholesterolaemia
Familial hypercholesterolaemia is an inherited disorder characterised by impaired clearance of low-density lipoprotein (LDL) cholesterol from the circulation.
The condition most commonly results from mutations affecting the LDL receptor pathway. As a consequence, LDL cholesterol accumulates throughout life, accelerating atherosclerosis and increasing cardiovascular risk.
Key Genetic Causes
The most important mutations include:
LDLR mutations (most common)
APOB mutations
PCSK9 gain-of-function mutations
Rare defects affecting LDL receptor processing
Inheritance is typically autosomal dominant.
Heterozygous versus Homozygous FH
Distinguishing heterozygous from homozygous disease is a favourite MRCP examination theme.
Feature | Heterozygous FH | Homozygous FH |
Frequency | Relatively common | Rare |
LDL cholesterol | Markedly elevated | Extremely elevated |
Cardiovascular disease | Early adulthood | Childhood or adolescence |
Tendon xanthomas | Common | Very common |
Response to statins | Usually good | Often limited |
Prognosis untreated | Premature CAD | Severe early CAD |
High-Yield Examination Pearl
Patients with homozygous FH may develop severe coronary artery disease and myocardial infarction during childhood or adolescence.
Characteristic Lipid Profile
The lipid profile in classical familial hypercholesterolaemia is highly recognisable.
Typical Findings
Markedly elevated LDL cholesterol
Elevated total cholesterol
Normal or near-normal triglycerides
Increased apolipoprotein B concentrations
MRCP questions often test recognition of isolated LDL elevation, particularly when combined with a family history of premature coronary disease.
Clinical Features You Must Recognise
Tendon Xanthomas
Tendon xanthomas are cholesterol-rich deposits within tendons and are among the most characteristic findings in FH.
Common sites include:
Achilles tendon
Extensor tendons of the hands
The presence of tendon xanthomas should immediately raise suspicion for familial hypercholesterolaemia.
Xanthelasma
Xanthelasma consists of yellow cholesterol-rich plaques around the eyelids.
Although commonly associated with lipid disorders, it is less specific than tendon xanthomas.
Corneal Arcus
A corneal lipid ring occurring in younger individuals is suggestive of inherited lipid disorders.
Premature Atherosclerotic Disease
Patients may present with:
Stable angina
Acute coronary syndromes
Peripheral arterial disease
Cerebrovascular disease
The risk increases because elevated LDL cholesterol is present from birth.
Diagnosis
Diagnosis relies upon a combination of:
Lipid measurements
Family history
Clinical examination
Genetic testing
The Dutch Lipid Clinic Network Criteria are widely used in specialist practice.
For MRCP Part 1, candidates should prioritise recognising:
Markedly elevated LDL cholesterol
Tendon xanthomas
Family history of premature coronary artery disease
Autosomal dominant inheritance
Family Screening
Cascade screening of first-degree relatives is recommended because of the inherited nature of the condition.
Further information is available from NICE:
The 10 Highest-Yield MRCP Facts
Familial hypercholesterolaemia is usually autosomal dominant.
LDL receptor mutations are the commonest cause.
LDL cholesterol is markedly elevated.
Triglycerides are usually normal.
Tendon xanthomas are highly characteristic.
Achilles tendon involvement is common.
Premature coronary artery disease is the major complication.
Homozygous disease presents much earlier than heterozygous disease.
Statins are first-line treatment.
Family cascade screening is recommended.
Management
Lifestyle Modification
Although FH is genetic, lifestyle interventions remain important.
Recommended measures include:
Smoking cessation
Regular physical activity
Weight optimisation
Reduction in saturated fat intake
Blood pressure control
Diabetes management where appropriate
Pharmacological Therapy
Statins
High-intensity statins are first-line treatment.
Examples include:
Atorvastatin
Rosuvastatin
These reduce LDL cholesterol and significantly lower cardiovascular risk.
Ezetimibe
Ezetimibe may be added when LDL targets are not achieved with statin therapy alone.
PCSK9 Inhibitors
Patients with severe disease may benefit from:
Evolocumab
Alirocumab
These agents substantially reduce LDL cholesterol by enhancing LDL receptor recycling.
Information from the European Society of Cardiology can be found here:
Lipoprotein Apheresis
Reserved for selected patients with severe homozygous disease or refractory hypercholesterolaemia.
The Five Most Tested Subtopics
1. LDL Receptor Defects
The single most important molecular mechanism.
2. Tendon Xanthomas
A classic clinical clue that frequently appears in examination questions.
3. Premature Coronary Artery Disease
The major cause of morbidity and mortality.
4. Autosomal Dominant Inheritance
A recurring genetics question theme.
5. Lipid-Lowering Therapy
Candidates should know statins remain first-line treatment.
Mini-Case: Exam-Style Question
A 35-year-old man presents with exertional chest pain. His father died from a myocardial infarction at the age of 43 years. Examination reveals bilateral Achilles tendon xanthomas. Blood tests show:
Total cholesterol: markedly elevated
LDL cholesterol: markedly elevated
Triglycerides: normal
What is the most likely diagnosis?
A. Familial combined hyperlipidaemiaB. Familial hypercholesterolaemiaC. Secondary hyperlipidaemia due to hypothyroidismD. Type 2 diabetes mellitusE. Hypertriglyceridaemia syndrome
Answer
B. Familial hypercholesterolaemia
Explanation
The combination of tendon xanthomas, a strong family history of premature coronary disease and isolated LDL elevation is highly characteristic of familial hypercholesterolaemia.
For additional exam-style practice questions, explore:
Practical Study Checklist
Before the examination, ensure you can confidently:
Explain the inheritance pattern of FH.
Identify LDL receptor mutations as the commonest cause.
Describe the typical lipid profile.
Recognise tendon xanthomas.
Differentiate tendon xanthomas from xanthelasma.
Compare heterozygous and homozygous disease.
Explain why cardiovascular risk is markedly increased.
Identify first-line pharmacological therapy.
Understand the role of PCSK9 inhibitors.
Explain the importance of family screening.
Common Pitfalls
1. Confusing Xanthelasma with Tendon Xanthomas
Tendon xanthomas are far more specific for FH.
2. Assuming Triglycerides Are Markedly Elevated
Classical FH is characterised by elevated LDL cholesterol rather than hypertriglyceridaemia.
3. Forgetting the Genetic Pattern
Most cases are inherited in an autosomal dominant fashion.
4. Missing the Significance of Family History
Premature coronary artery disease in relatives is a major diagnostic clue.
5. Overlooking Homozygous Disease
Homozygous FH presents earlier and is considerably more severe.
Related MRCP Revision Resources
To strengthen your understanding of metabolic medicine and cardiovascular risk:
MRCP Part 1 Hub: https://www.crackmedicine.co.in/mrcp-part-1/
MRCP Question Bank: https://www.crackmedicine.co.in/qbank/
MRCP Lectures: https://www.crackmedicine.co.in/lectures/
MRCP Mock Tests: https://www.crackmedicine.co.in/mock-tests/
Suggested related topics:
Dyslipidaemia and lipid-lowering therapy
Cardiovascular risk assessment
Prevention of atherosclerotic cardiovascular disease
Diabetes and cardiovascular complications
Inherited metabolic disorders
FAQs
Is familial hypercholesterolaemia autosomal dominant?
Yes. Most cases are inherited in an autosomal dominant pattern, meaning first-degree relatives have a significant risk of being affected.
What lipid abnormality is most characteristic of FH?
Marked elevation of LDL cholesterol with normal or near-normal triglycerides is the classical finding.
What physical sign is most specific for familial hypercholesterolaemia?
Tendon xanthomas, particularly involving the Achilles tendon, are among the most specific clinical findings.
What is the first-line treatment for FH?
High-intensity statin therapy is the cornerstone of treatment and significantly reduces cardiovascular risk.
Why is familial hypercholesterolaemia frequently tested in MRCP Part 1?
It combines genetics, metabolism and cardiovascular medicine while demonstrating a classic association between inherited disease and premature coronary artery disease.
Ready to start
Preparing for MRCP Part 1 requires repeated exposure to high-yield clinical scenarios. Strengthen your understanding of metabolic medicine through the MRCP Part 1 overview, practise with Free MRCP MCQs and assess your readiness using our mock tests.
Sources
MRCP(UK) Examination Information and Curriculum: https://www.mrcpuk.org/
NICE Guideline CG71: Familial Hypercholesterolaemia: https://www.nice.org.uk/guidance/cg71
European Society of Cardiology Dyslipidaemia Guidelines: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Dyslipidaemias-management-of
NHS Familial Hypercholesterolaemia Overview: https://www.nhs.uk/conditions/familial-hypercholesterolaemia/
British Heart Foundation Information on FH: https://www.bhf.org.uk/informationsupport/conditions/inherited-heart-conditions/familial-hypercholesterolaemia
Comments